Virologists from the KU Leuven Rega Institute in Belgium have proven that a remedy with the anti-malaria drug hydroxychloroquine doesn’t restrict SARS-CoV-2 coronavirus replication in hamsters. A excessive dose of the anti-flu drug favipiravir, in contrast, has an antiviral impact within the hamsters. The crew printed their findings within the Proceedings of the Nationwide Academy of Sciences (PNAS).
Virologists on the KU Leuven Rega Institute have been engaged on two strains of SARS-CoV-2 analysis: looking for a vaccine to stop an infection, and testing present medication to see which one can scale back the quantity of virus in contaminated folks.
To check the efficacy of the vaccine and antivirals preclinically, the researchers use hamsters. The rodents are notably appropriate for SARS-CoV-2 analysis as a result of the virus replicates itself strongly in hamsters after an infection. Furthermore, hamsters develop a lung pathology much like delicate COVID-19 in people. This isn’t the case with mice, for instance.
For this examine, the crew of Suzanne Kaptein (PhD), Joana Rocha-Pereira (PhD), Professor Leen Delang, and Professor Johan Neyts gave the hamsters both hydroxychloroquine or favipiravir — a broad-spectrum antiviral drug utilized in Japan to deal with influenza — for 4 to 5 days. They examined a number of doses of favipiravir. The hamsters had been contaminated with the SARS-CoV-2 virus in two methods: by inserting a excessive dose of virus straight into their noses or by placing a wholesome hamster in a cage with an contaminated hamster. Drug remedy was began one hour earlier than the direct an infection or in the future earlier than the publicity to an contaminated hamster. 4 days after an infection or publicity, the researchers measured how a lot of the virus was current within the hamsters.
Hydroxychloroquine versus favipiravir
Remedy with hydroxychloroquine had no impression: the virus ranges didn’t lower and the hamsters had been nonetheless infectious. “Regardless of the dearth of clear proof in animal fashions or medical research, many COVID-19 sufferers have already been handled with hydroxychloroquine,” explains Joana Rocha-Pereira. “Based mostly on these outcomes and the outcomes of different groups, we advise in opposition to additional exploring using hydroxychloroquine as a remedy in opposition to COVID-19.”
A excessive dose of favipiravir, nonetheless, had a potent impact. A couple of days after the an infection, the virologists detected hardly any infectious virus particles within the hamsters that acquired this dose and that had been contaminated intranasally. Furthermore, hamsters that had been in a cage with an contaminated hamster and had been given the drug didn’t develop an apparent an infection. Those who had not acquired the drug all turned contaminated after having shared a cage with an contaminated hamster.
A low dose of the drug favipiravir didn’t have this end result. “Different research that used a decrease dose had comparable outcomes,” Professor Delang notes. “The excessive dose is what makes the distinction. That is vital to know, as a result of a number of medical trials have already been set as much as check favipiravir on people.”
The researchers are cautiously optimistic about favipiravir. “As a result of we administered the drug shortly earlier than exposing the hamsters to the virus, we may set up that the medication can be used prophylactically, so in prevention,” Suzanne Kaptein notes.
“If additional analysis exhibits that the outcomes are the identical in people, the drug might be used proper after somebody from a high-risk group has come into contact with an contaminated individual. It might probably even be energetic through the early levels of the illness.”
Common preventive use might be not an choice, nonetheless, as a result of it’s not recognized whether or not long-term use, particularly at a excessive dose, has unintended effects.
Additional analysis should decide whether or not people can tolerate a excessive dose of favipiravir. “Within the hamsters, we detected hardly any unintended effects,” says Delang. Up to now, the drug has already been prescribed in excessive doses to Ebola sufferers, who seem to have tolerated it nicely.
“Favipiravir just isn’t a panacea,” the researchers warn. This flu drug, nor another drug, has not been particularly developed in opposition to coronaviruses. Because of this, the efficiency of favipiravir is to be thought of reasonable at finest.
The examine additionally highlights the significance of utilizing small animals to check therapies in opposition to SARS-CoV-2 in vivo. “Our hamster mannequin is ideally suited to establish which new or present medication could also be thought of for medical research,” explains Professor Johan Neyts. “Within the early days of the pandemic, such a mannequin was not but accessible. At the moment, the one choice was to discover in sufferers whether or not or not a drug corresponding to hydroxychloroquine may assist them. Nonetheless, testing remedies on hamsters supplies essential data that may forestall the lack of precious time and vitality with medical trials on medication that do not work.”
Not all analysis fashions are equal
Kaptein, Rocha-Pereira, Delang and Neyts not too long ago contributed to a commentary in Nature Communications during which they offer further context to the contradictory messages which were circulating about (hydroxy)chloroquine. Within the early days of the pandemic, a number of research had been set as much as check these medication in cell cultures. The outcomes prompt that they might have an antiviral impact. Because of this, medical trials had been organised to check the medication on people. Nonetheless, cell cultures aren’t the most effective proxy for the human physique, and no conclusive impact was present in people.
Of their commentary, the authors describe a number of current research on human organ-on-chip and different advanced in vitro fashions, mice, hamsters, and non-human primates. Every of those research demonstrates that hydroxychloroquine and chloroquine do not need the efficacy prompt by the research in cell cultures. Due to this fact, the authors conclude that these malaria medication are most unlikely to be efficient in people as a COVID-19 remedy.
The examine “Favipiravir at excessive doses has potent antiviral exercise in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks exercise” by Suzanne Kaptein, Johan Neyts, Joana Rocha-Pereira, Leen Delang et al. was printed in PNAS.
The commentary “Rising preclinical proof doesn’t assist broad use of hydroxychloroquine in COVID-19 sufferers” by Funnell et al. was printed in Nature Communications (open entry).